| Date | Title | Description |
| 08.07.2022 | Solasia acquires episil oral liquid business from Camurus | Solasia acquires episil oral liquid business from Camurus
Fri, Jul 08, 2022 08:30 CET Report this content
Lund, Sweden and Tokyo, Japan — 8 July 2022 — Camurus AB (NASDAQ STO: CAMX, hereinafter “Camurus”) and Solasia Pharma K.K. (TSE: 4597,... |
| 24.11.2021 | Solasia Pharma K K : Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer | To: All Concerned Parties November 24, 2021
Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8045
URL: htt... |
| 10.11.2021 | Solasia Announces Revision to Full-Year Earnings Forecast | To: All Concerned Parties November 10, 2021
Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: htt... |
| 30.06.2021 | Solasia Pharma K K : Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan | NEWS RELEASE
Solasia Announces Submission of New Drug Application for Anti-cancer Drug
DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan
NDA filed in Japan ahead of anywhere else in the world
New anti-cancer drug with a novel mechanism o... |
| 30.06.2021 | Solasia Pharma K K : Announces Exercise Price Revisions Associated with Series 12 Warrants | To: All Concerned Parties June 30, 2021
Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049
URL: https:/... |
| 31.05.2021 | SOLASIA PHARMA K.K.
Solasia Pharma K K : Announces episil was Recommended in Guidelines for Oral Mucositis Caused by Anti-tumor Therapy by CSCO | NEWS RELEASE
THE FIRST "EXPERT CONSENSUS ON DIAGNOSIS, PREVENTION AND TREATMENT OF ACUTE ORAL MUCOSITIS CAUSED BY ANTI-TUMOR THERAPY" IN CHINA WAS RELEASED, AND EPISIL® WAS RECOMMENDED BY THE GUIDELINES
TOKYO, Japan, May 31, 2021 ... |
| 14.05.2021 | SOLASIA PHARMA K.K.
Solasia Pharma K K : Announces Completion of Exercise of Series 11 Warrants | To: All Concerned Parties May 14, 2021
Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049
URL: https://... |
| 06.05.2021 | SOLASIA PHARMA K.K.
Solasia Pharma K K : Partner, Isofol Announces Global Phase III AGENT Study for arfolitixorin(SP-05) Completed Recruitment of Japanese Patients | To: All Concerned Parties May 6, 2021
Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049
URL: https://s... |
